Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.
The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.
advertisement
In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Websites selling Wegovy, Zepbound ingredients targeted by FDA
Next article： In age of alternative facts, a scholarly course on calling out crap
Next article： In age of alternative facts, a scholarly course on calling out crap
